

Freedom of Information Act 2000

The Royal Cornwall Hospitals NHS Trust Response to Information request

Date Request Received: 10 October 2025

FOI Ref 30632

Requested Information:

I have a freedom of information request regarding the treatment of renal cell carcinoma. Could you please answer the following questions:

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

- Avelumab + Axitinib
- Axinitib
- Cabozantinib
- Everolimus
- Lenvatinib + Everolimus
- Lenvatinib + Pembrolizumab
- Nivolumab monotherapy
- Nivolumab + Cabozantinib
- Nivolumab + Ipilimumab
- Pazopanib
- Pembrolizumab monotherapy
- Pembrolizumab + Axitinib
- Radiotherapy only
- Sunitinib
- Temsirolimus
- Tivozanib
- Other active systemic anti-cancer therapy
- Palliative care only

Q2. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:

- Avelumab + Axitinib (Bavencio + Inlyta)
- Cabozantinib (Cometriq)
- Nivolumab (Opdivo)
- Nivolumab + Cabozantinib (Opdivo + Cometriq)
- Nivolumab + Ipilimumab (Opdivo + Yervoy)
- Lenvatinib + Pembrolizumab + (Kispalyx + Keytruda)

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?

- Nivolumab (monotherapy)
- Nivolumab + Ipilimumab
- Nivolumab + Cabozantinib
- Avelumab + Axitinib
- Lenvatinib + Pembrolizumab + (Kispix + Keytruda)

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Q5. Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so, please provide the name of each trial and number of patients that are taking part?

Response:

Data from June to August 2025

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

- Avelumab + Axitinib **5**
- Axitinib **2**
- Cabozantinib **13**
- Everolimus
- Lenvatinib + Everolimus **2**
- Lenvatinib + Pembrolizumab **3**
- Nivolumab monotherapy **8**
- Nivolumab + Cabozantinib **4**
- Nivolumab + Ipilimumab **3**
- Pazopanib **5**
- Pembrolizumab monotherapy **13**
- Pembrolizumab + Axitinib **0**
- Radiotherapy only **2** 1st treatment starts determined by ICD10 code C64X
- Sunitinib **0**
- Temsirolimus **0**
- Tivozanib **2**
- Other active systemic anti-cancer therapy **3**
- Palliative care only **1** 1st treatment starts determined by ICD10 code C64X

Q2. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:

- Avelumab + Axitinib (Bavencio + Inlyta) **5**
- Cabozantinib (Cometriq) **13**
- Nivolumab (Opdivo) **8**
- Nivolumab + Cabozantinib (Opdivo + Cometriq) **4**
- Nivolumab + Ipilimumab (Opdivo + Yervoy) **3**
- Lenvatinib + Pembrolizumab + (Kisplyx + Keytruda) **3**

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?

- Nivolumab (monotherapy) **0**
- Nivolumab + Ipilimumab **1**
- Nivolumab + Cabozantinib **0**
- Avelumab + Axitinib **2**
- Lenvatinib + Pembrolizumab + (Kisplyx + Keytruda) **0**

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

22 patients have undergone one of these procedures at Royal Cornwall Hospitals Trust, 17 were for cancer treatment during this period. In addition to the above, University Hospitals Plymouth undertook 4 cancer-related nephrectomies on behalf of RCHT

Q5. Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so, please provide the name of each trial and number of patients that are taking part?

Yes, although there are currently no renal cell carcinoma trials open to recruitment at Royal Cornwall Hospitals Trust.

Attachment(s):

No Attachment(s)

Date Response sent: 23 October 2025